Treatment of Relapsed Acute Myeloid Leukemia.
Thol F, Ganser A.
Curr Treat Options Oncol. 2020 Jun 29;21(8):66. doi: 10.1007/s11864-020-00765-5.
A review of treatment options employed in relapsed/refractory AML.
Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K.
Hematology. 2023 Dec;28(1):2196482. doi: 10.1080/16078454.2023.2196482.
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I.
Int J Hematol. 2022 Jun;115(6):762-777. doi: 10.1007/s12185-022-03353-5. Epub 2022 May 9.
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N.
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Li R, Wang Z, Zhang Y, Guo M, Ni X, Chen J, Chen L, Gao L, Gong S, Tang G, Yang J, Wang J.
Ann Hematol. 2023 Jan;102(1):89-97. doi: 10.1007/s00277-022-05061-w. Epub 2022 Dec 21.
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M.
JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605.
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study.
Klein K, Beverloo HB, Zimmermann M, Raimondi SC, von Neuhoff C, de Haas V, van Weelderen R, Cloos J, Abrahamsson J, Bertrand Y, Dworzak M, Fynn A, Gibson B, Ha SY, Harrison CJ, Hasle H, Elitzur S, Leverger G, Maschan A, Razzouk B, Reinhardt D, Rizzari C, Smisek P, Creutzig U, Kaspers GJL.
Pediatr Blood Cancer. 2022 Jan;69(1):e29341. doi: 10.1002/pbc.29341. Epub 2021 Sep 17.
Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
Ertz-Archambault N, Kosiorek H, Slack JL, Lonzo ML, Greipp PT, Khera N, Kelemen K.
Biol Blood Marrow Transplant. 2017 May;23(5):782-789. doi: 10.1016/j.bbmt.2017.02.003. Epub 2017 Feb 9.
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
van der Maas NG, Breems D, Klerk CPW, Pabst T, Gradowska P, Thomas A, Biemond BJ, Kuball J, Van Elssen CHMJ, Visser O, Vekemans MC, Graux C, Maertens J, Knapper S, Dennis M, Freeman S, Thomas I, Beverloo HB, Huls G, Craddock C, Valk PJM, Vyas P, Russell N, Ossenkoppele G, Löwenberg B, Cornelissen JJ, Versluis J.
Blood Adv. 2025 Aug 12;9(15):3853-3864. doi: 10.1182/bloodadvances.2025015797.
Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F, Kirkland MA, van Rhee FV, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NC.
Bone Marrow Transplant. 1996 Dec;18(6):1147-52.
